| Ticker Details |
Veru Inc.
Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility and novel chemotherapies for a variety of cancers.
|
| IPO Date: |
February 25, 1999 |
| Sector: |
Consumer Staples |
| Industry: |
Personal Products |
| Market Cap: |
$39M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.18 | 3.84%
|
| Avg Daily Range (30 D): |
$0.06 | 2.31%
|
| Avg Daily Range (90 D): |
$0.07 | 2.88%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
2.01M |
| Avg Daily Volume (30 D): |
.05M |
| Avg Daily Volume (90 D): |
.09M |
| Trade Size |
| Avg Trade Size (Sh.): |
199 |
| Avg Trade Size (Sh.) (30 D): |
140 |
| Avg Trade Size (Sh.) (90 D): |
140 |
| Institutional Trades |
| Total Institutional Trades: |
665 |
| Avg Institutional Trade: |
$1.41M |
| Avg Institutional Trade (30 D): |
$2.88M |
| Avg Institutional Trade (90 D): |
$2.88M |
| Avg Institutional Trade Volume: |
.02M |
| Avg Institutional Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.71M |
| Avg Closing Trade (30 D): |
$6.81M |
| Avg Closing Trade (90 D): |
$6.81M |
| Avg Closing Volume: |
29.6K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$-.71
|
$-.26
|
$.1
|
|
Diluted EPS
|
|
|
|
|
Revenue
|
$10.09M
|
$M
|
$8.63M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$-12.07M
|
$-5.33M
|
$8.5M
|
|
Operating Income / Loss
|
$-19.93M
|
$-5.42M
|
$1.17M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$-10.77M
|
$M
|
$.83M
|
|
PE Ratio
|
|
|
|
|
|
|
